AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, ...

AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...

If you often feel short of breath when you talk, walk a short distance, or use the stairs, you might think it is just a ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...

On January 5, 2026, under Health and Human Services Secretary Kennedy's leadership, the Centers for Disease Control and Prevention (CDC) released changes to America's longstanding vaccination ...

Patients who have comorbid COPD with heart failure and ischemic heart disease have increased health care resource use and higher mortality.

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

Background The relationship of social determinants of health (SDOH), environmental exposures and medical history to lung function trajectories is underexplored. A better understanding of these ...

The treatment of chronic obstructive pulmonary disease (COPD) has been guided for decades by robust clinical practice guidelines (CPGs), such as NICE1 and GesEPOC,2 as well as international ...

Healio Pulmonology has compiled the top news on COPD posted in 2025.Readers were most interested in how pulmonary ...

COPD inhaled triple therapy (BDP/FF/G) improved symptoms, lung function, adherence, and QOL in patients previously treated with inhaled dual therapy.